Syntis Bio Secures $38M Series A, Accelerates Oral Therapy Pipeline
July 9, 2025, 3:31 am
Syntis Bio, a Boston biopharma, secured $38M Series A funding led by Cerberus Ventures. An additional $5M from NIH non-dilutive grants was also obtained. This substantial capital propels the development of oral therapies for obesity, diabetes, and rare diseases. The company's SYNT platform harnesses small intestine biology. Funds will advance lead obesity program SYNT-101 into Phase 1 studies. SYNT-202, a rare disease therapy for homocystinuria, also initiates Phase 1. This investment underscores confidence in Syntis Bio's innovative approach. It promises to revolutionize drug delivery and patient access with its groundbreaking oral treatments.
Syntis Bio, a pioneering biopharmaceutical firm, has announced significant financial success. The Boston-based company completed an oversubscribed $38 million Series A financing round. This substantial capital infusion fuels its mission. It develops transformative oral therapies. These treatments target widespread conditions. They also address rare, underserved diseases. The funding round garnered strong investor confidence. Cerberus Ventures spearheaded the Series A investment.
Additional capital boosts the company’s efforts. Syntis Bio also secured up to $5 million. This non-dilutive funding comes from the National Institutes of Health (NIH). Specifically, two Fast-Track Small Business Innovation Research (SBIR) awards from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) provided the grants. This combined financial backing, totaling $43 million in new capital, marks a pivotal moment for the company.
A robust syndicate of investors joined the Series A. New participants include Mansueto Investments, Woori Venture Partners, and Apollo Labs. BOLD Capital Partners, W. R. Berkley Corporation, Safar Partners, and Portal Innovations also contributed. Colorcon Ventures and Cerity Partners Ventures completed the diverse group. This wide-ranging support highlights the market's belief in Syntis Bio’s innovative platform. It underscores the urgent need for advanced oral therapies.
Syntis Bio operates as a clinical-stage biopharmaceutical company. Its core strategy is unique. It harnesses the small intestine’s innate biology. This approach creates more accessible, effective, and sustainable healthcare solutions. The small intestine is vital. It serves as the body’s nexus for metabolic control. It plays a key role in digestion and drug absorption. Targeting this area offers profound therapeutic potential.
The company's proprietary SYNT™ (SYNthetic Tissue-lining) platform is central. This technology involves an orally delivered, transient polymer coating. This coating specifically targets the small intestine. It acts as a regulator. It controls nutrient uptake effectively. It enhances the efficacy of gut-restricted enzymes. Furthermore, it significantly increases systemic drug absorption. This effect can last for up to 24 hours. The platform represents a fundamentally novel approach to drug delivery.
Capital from this financing and grant funding has clear objectives. It will significantly advance the development of the SYNT platform. It will also expand Syntis Bio's operational capabilities. Research and development efforts will intensify. These investments accelerate the journey of pipeline candidates. The goal is bringing innovative treatments closer to patients.
A primary focus is SYNT-101. This is Syntis Bio’s lead obesity program. It is engineered as a once-daily oral treatment. The new funds will advance SYNT-101 through critical Phase 1 studies. Preclinical data for SYNT-101 has shown strong promise. It demonstrated robust safety profiles. Significant weight loss data was also observed. Clinical advancements confirm its safety and mechanism of action. Pathways for controlling weight are also being elucidated. This progress validates the program’s potential. It offers a new hope for millions affected by obesity.
The funding also enables another crucial step. Syntis Bio will initiate Phase 1 studies for SYNT-202. This drug is a first-in-class oral enzyme therapy. It targets homocystinuria. Homocystinuria is a rare pediatric amino acid disorder. This condition lacks effective oral treatments. SYNT-202’s advancement could provide a much-needed solution. It exemplifies Syntis Bio's commitment to orphan metabolic diseases.
Syntis Bio's pipeline extends beyond these lead programs. It includes a broader portfolio of therapies. These therapies target various orphan metabolic diseases. They also address intestinal-related disorders. The SYNT platform's versatility is a key asset. It allows for diverse applications. Each aims to improve patient outcomes significantly.
The demand for accessible oral therapies is growing. Current treatments for chronic and rare diseases often involve complex, high-cost development processes. These factors limit patient access to essential medicines. Syntis Bio’s platform offers a solution. It simplifies drug delivery. It reduces the burden on patients. It also potentially lowers healthcare costs.
Rahul Dhanda leads Syntis Bio as CEO. His vision guides the company. It seeks to revolutionize chronic and rare disease treatment. The emphasis is on safe and effective oral therapies. The oversubscribed Series A round and non-dilutive grants validate this vision. They accelerate the promise of the SYNT platform. This platform unlocks the small intestine’s full therapeutic potential. It aims to meaningfully improve human health on a global scale.
The investment community recognizes this potential. The SYNT platform's breakthrough technology is disruptive. It represents a fundamental shift in oral biologic delivery. This innovation promises to expand patient access. It redefines what is possible in drug delivery. This could bring significant advancements to patients worldwide.
Syntis Bio’s recent funding success marks a critical juncture. It empowers the company to accelerate its research. It allows for expanded operations. Most importantly, it fast-tracks the development of groundbreaking oral therapies. These treatments promise to reshape how prevalent and rare diseases are managed. The future of healthcare looks increasingly accessible and effective, thanks to such advancements.
Syntis Bio, a pioneering biopharmaceutical firm, has announced significant financial success. The Boston-based company completed an oversubscribed $38 million Series A financing round. This substantial capital infusion fuels its mission. It develops transformative oral therapies. These treatments target widespread conditions. They also address rare, underserved diseases. The funding round garnered strong investor confidence. Cerberus Ventures spearheaded the Series A investment.
Additional capital boosts the company’s efforts. Syntis Bio also secured up to $5 million. This non-dilutive funding comes from the National Institutes of Health (NIH). Specifically, two Fast-Track Small Business Innovation Research (SBIR) awards from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) provided the grants. This combined financial backing, totaling $43 million in new capital, marks a pivotal moment for the company.
A robust syndicate of investors joined the Series A. New participants include Mansueto Investments, Woori Venture Partners, and Apollo Labs. BOLD Capital Partners, W. R. Berkley Corporation, Safar Partners, and Portal Innovations also contributed. Colorcon Ventures and Cerity Partners Ventures completed the diverse group. This wide-ranging support highlights the market's belief in Syntis Bio’s innovative platform. It underscores the urgent need for advanced oral therapies.
Syntis Bio operates as a clinical-stage biopharmaceutical company. Its core strategy is unique. It harnesses the small intestine’s innate biology. This approach creates more accessible, effective, and sustainable healthcare solutions. The small intestine is vital. It serves as the body’s nexus for metabolic control. It plays a key role in digestion and drug absorption. Targeting this area offers profound therapeutic potential.
The company's proprietary SYNT™ (SYNthetic Tissue-lining) platform is central. This technology involves an orally delivered, transient polymer coating. This coating specifically targets the small intestine. It acts as a regulator. It controls nutrient uptake effectively. It enhances the efficacy of gut-restricted enzymes. Furthermore, it significantly increases systemic drug absorption. This effect can last for up to 24 hours. The platform represents a fundamentally novel approach to drug delivery.
Capital from this financing and grant funding has clear objectives. It will significantly advance the development of the SYNT platform. It will also expand Syntis Bio's operational capabilities. Research and development efforts will intensify. These investments accelerate the journey of pipeline candidates. The goal is bringing innovative treatments closer to patients.
A primary focus is SYNT-101. This is Syntis Bio’s lead obesity program. It is engineered as a once-daily oral treatment. The new funds will advance SYNT-101 through critical Phase 1 studies. Preclinical data for SYNT-101 has shown strong promise. It demonstrated robust safety profiles. Significant weight loss data was also observed. Clinical advancements confirm its safety and mechanism of action. Pathways for controlling weight are also being elucidated. This progress validates the program’s potential. It offers a new hope for millions affected by obesity.
The funding also enables another crucial step. Syntis Bio will initiate Phase 1 studies for SYNT-202. This drug is a first-in-class oral enzyme therapy. It targets homocystinuria. Homocystinuria is a rare pediatric amino acid disorder. This condition lacks effective oral treatments. SYNT-202’s advancement could provide a much-needed solution. It exemplifies Syntis Bio's commitment to orphan metabolic diseases.
Syntis Bio's pipeline extends beyond these lead programs. It includes a broader portfolio of therapies. These therapies target various orphan metabolic diseases. They also address intestinal-related disorders. The SYNT platform's versatility is a key asset. It allows for diverse applications. Each aims to improve patient outcomes significantly.
The demand for accessible oral therapies is growing. Current treatments for chronic and rare diseases often involve complex, high-cost development processes. These factors limit patient access to essential medicines. Syntis Bio’s platform offers a solution. It simplifies drug delivery. It reduces the burden on patients. It also potentially lowers healthcare costs.
Rahul Dhanda leads Syntis Bio as CEO. His vision guides the company. It seeks to revolutionize chronic and rare disease treatment. The emphasis is on safe and effective oral therapies. The oversubscribed Series A round and non-dilutive grants validate this vision. They accelerate the promise of the SYNT platform. This platform unlocks the small intestine’s full therapeutic potential. It aims to meaningfully improve human health on a global scale.
The investment community recognizes this potential. The SYNT platform's breakthrough technology is disruptive. It represents a fundamental shift in oral biologic delivery. This innovation promises to expand patient access. It redefines what is possible in drug delivery. This could bring significant advancements to patients worldwide.
Syntis Bio’s recent funding success marks a critical juncture. It empowers the company to accelerate its research. It allows for expanded operations. Most importantly, it fast-tracks the development of groundbreaking oral therapies. These treatments promise to reshape how prevalent and rare diseases are managed. The future of healthcare looks increasingly accessible and effective, thanks to such advancements.